Mouse Models of NMNAT1-Leber Congenital Amaurosis (LCA9) Recapitulate Key Features of the Human Disease
Scott H. Greenwald(Massachusetts Eye and Ear Infirmary), Eric A. Pierce(Broad Institute), Patsy M. Nishina(Unknown), Lisa Stone(Jackson Laboratory), Lan Ying Shi(Jackson Laboratory), Mark P. Krebs(Jackson Laboratory), Gayle B. Collin(Jackson Laboratory), Jeremy R. Charette(Jackson Laboratory), Qin Liu(Massachusetts Eye and Ear Infirmary), Steve D. M. Brown(Mary Lyon Centre at MRC Harwell), Magdalena Staniszewska(SDS Optic (Poland)), Wanda L. Hicks(Jackson Laboratory), Michael R. Bowl(University College London)
Cited by 46
Related Papers
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
|Proceedings of the National Academy of Sciences|1995|1k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
α-Synuclein impairs macroautophagy: implications for Parkinson’s disease
|The Journal of Cell Biology|2010|833